Stocks and Investing Stocks and Investing
Tue, February 7, 2017

Matthew Harrison Initiated (BMRN) at Buy and Held Target at $110 on, Feb 7th, 2017


Published on 2024-10-25 20:11:14 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy and Held Target at $110 on, Feb 7th, 2017.

Matthew has made no other calls on BMRN in the last 4 months.



There are 4 other peers that have a rating on BMRN. Out of the 4 peers that are also analyzing BMRN, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Downgraded from Buy to Hold and Decreased Target to $105 on, Tuesday, November 29th, 2016
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Kennen MacKay of "Credit Suisse" Initiated at Buy with Decreased Target to $107 on, Monday, January 23rd, 2017
  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016
Contributing Sources